Back to Search
Start Over
Osteosarcoma in Children: Not Only Chemotherapy
- Source :
- Pharmaceuticals, Pharmaceuticals, Vol 14, Iss 923, p 923 (2021)
- Publication Year :
- 2021
- Publisher :
- MDPI AG, 2021.
-
Abstract
- Osteosarcoma (OS) is the most severe bone malignant tumor, responsible for altered osteoid deposition and with a high rate of metastasis. It is characterized by heterogeneity, chemoresistance and its interaction with bone microenvironment. The 5-year survival rate is about 67% for patients with localized OS, while it remains at 20% in case of metastases. The standard therapy for OS patients is represented by neoadjuvant chemotherapy, surgical resection, and adjuvant chemotherapy. The most used chemotherapy regimen for children is the combination of high-dose methotrexate, doxorubicin, and cisplatin. Considered that the necessary administration of high-dose chemotherapy is responsible for a lot of acute and chronic side effects, the identification of novel therapeutic strategies to ameliorate OS outcome and the patients’ life expectancy is necessary. In this review we provide an overview on new possible innovative therapeutic strategies in OS.
- Subjects :
- Oncology
medicine.medical_specialty
medicine.medical_treatment
proteasome inhibitors
Pharmaceutical Science
Review
Metastasis
Pharmacy and materia medica
lncRNA
osteosarcoma
Internal medicine
Drug Discovery
medicine
Doxorubicin
Survival rate
Cisplatin
therapy
iron chelation
Chemotherapy
business.industry
chemoresistance
medicine.disease
Chemotherapy regimen
RS1-441
TKIs
Medicine
Molecular Medicine
Osteosarcoma
Methotrexate
immunotherapy
business
medicine.drug
Subjects
Details
- ISSN :
- 14248247
- Volume :
- 14
- Database :
- OpenAIRE
- Journal :
- Pharmaceuticals
- Accession number :
- edsair.doi.dedup.....912800a269b307bac04286e2446240fb
- Full Text :
- https://doi.org/10.3390/ph14090923